GSK Plc said its antibody drug Blenrep, which had its US clearance revoked last year, helped patients live longer without their blood cancer worsening in a late-stage study.
Volunteers taking the medicine with two other older ones fared better than a control group taking a standard regimen for a form of myeloma that returned after initial treatment, GSK said in a statement.
Blenrep is part of GSK’s push in cancer treatments but it suffered a setback last year when US regulators withdrew its clearance after a clinical trial failure.
The results announced Monday came from an intermediate analysis after the study was unblinded early on the advice of a monitoring panel.
Overall survival, a key efficacy measure, showed a “strong and clinically meaningful trend,” the UK drugmaker said, and the study will continue for a final analysis.
